Summary
Tirapazamine (TPZ) is a new anticancer drug that is activated specifically at the low oxygen level typically found in solid tumours. It exhibits preferential cytotoxicity towards hypoxic cells and has been shown in preclinical studies with transplanted tumours and in phase II and III clinical trials to potentiate the anti-tumour efficacy of cisplatin without increasing its systemic toxicity. At present, the mechanism for this potentiation is unknown. Here we show that there is a schedule-dependent enhancement of cisplatin cytotoxicity by TPZ for cells in vitro that is similar to that seen with transplanted murine tumours. This cisplatin potentiation depends on the TPZ exposure being at oxygen concentrations below 1%, which are typical of many cells in tumours but not in normal tissues. Also, the interaction between TPZ and cisplatin does not occur in cells mutant in ERCC4, a protein essential for repair of DNA interstrand cross-links. Incubation of the cells with TPZ under hypoxia prior to cisplatin treatment increases cisplatin-induced DNA interstrand cross-links with kinetics suggesting that TPZ inhibits or delays repair of the DNA cross-links. In conclusion, we show that the tumour-specific potentiation of cisplatin cytotoxicity is likely the result of an interaction between TPZ and cisplatin at the cellular level that requires the low oxygen levels typical of those in solid tumours. The mechanism of the interaction appears to be through a potentiation of cisplatin-induced DNA interstrand cross-links, possibly as a result of a diminished or delayed repair of these lesions
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adam, M., Gabalski, E. C., Oehlert, J. W., Bloch, D. A., Brown, J. M., Elsaid, A. A., Pinto, H. A. & Terris, D. J. (1999). Tissue oxygen distribution in head and neck patients. Head Neck 21: 146–153.
Andersson, B. S., Sadeghi, T., Siciliano, M. J., Legerski, R. & Murray, D. (1996). Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38: 406–416.
Berezney, R. & Coffey, D. S. (1975). Nuclear protein matrix: association with newly synthesized DNA. Science 189: 291–293.
Brizel, D. M., Rosner, G. L., Harrelson, J., Prosnitz, L. R. & Dewhirst, M. W. (1994). Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30: 635–642.
Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L. & Dewhirst, M. W. (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int I Radiat Oncol Biol Phys 38: 285–289.
Brown, J. M. (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163–1170.
Brown, J. M. & Lemmon, M. J. (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745–7749.
Brown, J. M. & Lemmon, M. J. (1991). Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20: 457–461.
Cook, P. R. (1989). The nucleoskeleton and the topology of transcription. Eur J Biochem 185: 487–501.
Cruickshank, G. S., Rampling, R. P. & Cowans, W. (1994). Direct measurement of the PO2 distribution in human malignant brain tumours. Adv Exp Med Biol 345: 465–470.
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C. & Reed, E. (1992). ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512–1517.
Damia, G., Imperatori, L., Stefanini, M. & D’Incalci, M. (1996). Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 66: 779–783.
Delahoussaye, Y. M., Wouters, B. G., Evans, J. E. & Brown, J. M. (1997). Intranuclear metabolism of tirapazamine by matrix-associated reductases. Proc Am Assoc Cancer Res 38: 163 (abstr. # 1095)
Dorie, M. J. & Brown, J. M. (1993). Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633–4636.
Dorie, M. J. & Brown, J. M. (1997). Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39: 361–366.
Durand, R. E. (1994). The influence of microenvironmental factors during cancer therapy. In vivo 8: 691–702.
Evans, J. E., Yudoh, K., Delahoussaye, Y. M. & Brown, J. M. (1998). Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res 58: 2098–2101.
Ewig, R. A. & Kohn, K. W. (1978). DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells. Cancer Res 38: 3197–3203.
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J. & Hartz, W. H. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831–838.
Graham, M. A., Senan, S., Robin, H., Eckhardt, N., Lendrem, D., Hincks, J., Greenslade, D., Rampling, R., Kaye, S. B., von Roemeling, R. & Workman, P. (1997). Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose escalation strategy in a phase I trial. Cancer Chemother Pharmacokin 40: 1–10.
Grau, C. & Overgaard, J. (1988). Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13: 301–309.
Hansson, J., Lewensohn, R., Ringborg, U. & Nilsson, B. (1987). Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47: 2631–2637.
Helmlinger, G., Yuan, F., Dellian, M. & Jain, R. K. (1997). Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177–182.
Hockel, M., Schlenger, K., Knoop, C. & Vaupel, P. (1991). Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 51: 6098–6102.
Jones, N. J., Stewart, S. A. & Thompson, L. H. (1990). Biochemical and genetic analysis of the Chinese hamster mutants irs1 and irs2 and their comparison to cultured ataxia telangiectasia cells. Mutagenesis 5: 15–23.
Kim, I. H. & Brown, J. M. (1994). Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29: 493–497.
Koch, C. J. (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53: 3992–3997.
Miller, V. A., Ng, K. K., Grant, S. C., Kindler, H., Pizzo, B., Heelan, R. T., von Roemeling, R. & Kris, M. G. (1997). Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8: 1269–1271.
Nordsmark, M., Bentzen, S. M. & Overgaard, J. (1994). Measurement of human tumour oxygenation status by a polarographic needle electrode. Acta Oncol 33: 383–389.
Nordsmark, M., Overgaard, M. & Overgaard, J. (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31–40.
Rodriguez, G. I., Valdivieso, M., Von Hoff, D. D., Kraut, M., Burris, H. A., Eckardt, J. R., Lockwood, G., Kennedy, H. & von Roemeling, R. (1996). A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15: 382 (abstract)
Siemann, D. W. (1996). The in situ tumour response to combinations of cyclophosphamide and tirapazamine. Br J Cancer 74: S65–69.
Siemann, D. W. & Hinchman, C. A. (1998). Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother Oncol 47: 215–220.
Treat, J., Haynes, B., Johnson, E., Belani, C., Greenberg, R., Rodriquez, R., Drobbins, P., Miller, W. J., Meehan, L. & von Roemeling, R. (1997). Tirapazamine with cisplatin: a phase II trial in advanced stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 1633 (abstract)
Treat, J., Johnson, E., Langer, C., Belani, C., Haynes, B., Greenberg, R., Rodriquez, R., Drobins, P., Miller, W., Meehan, L. Jr, McKeon, A., Devin, J., von Roemeling, R. & Viallet, J. (1998). Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16: 3524–3527.
Urtasun, R. C., Chapman, J. D., Raleigh, J. A., Franko, A. J. & Koch, C. J. (1986). Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 12: 1263–1267.
Vaupel, P. W. & Hockel, M. (1995). Oxygenation status of human tumors: a reappraisal using computerized pO2 histography. In: Tumor Oxygenation, Vaupel PW, Kelleher DK, Gunderoth MGustav Fischer Verlag: Stuttgart. 219–232.
Vaupel, P. W., Schlenger, K., Knoop, C. & Hockel, M. (1991). Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51: 3316–3322.
von Pawel, J. & von Roemeling, R. (1998). Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT 1 trial. Proc Am Soc Clin Oncol 17: 454a (Abstract)
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K. & Lee, W. W. (1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239–1242.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kovacs, M., Hocking, D., Evans, J. et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 80, 1245–1251 (1999). https://doi.org/10.1038/sj.bjc.6690492
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690492
Keywords
This article is cited by
-
A microfluidic chip of multiple-channel array with various oxygen tensions for drug screening
Microfluidics and Nanofluidics (2016)
-
Exploiting tumour hypoxia in cancer treatment
Nature Reviews Cancer (2004)
-
Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
British Journal of Cancer (2003)
-
DNA Damage Measured by the Comet Assay in Head and Neck Cancer Patients Treated with Tirapazamine
Neoplasia (1999)